DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, presented at this year’s annual American Association of Diabetes Care and Education Specialists conference. During the presentation, the company discussed a recent study that demonstrates the clinical strength of Dario’s AI-driven journey engine; specifically, DRIO’s research shows a 19% improvement in blood glucose readings. Dario’s conference presentation looked at the impact of personalized clinical interventions delivered in real-time through the company’s proprietary digital therapeutics platform. As part of the presentation, the company explains that the study tracked 3,609 Dario members, including individuals with Type 2 diabetes who were both insulin and non-insulin dependent; the group had recent clusters of high blood glucose readings, which is an indicator of poor health behaviors. According to the company, members of the test group received personalized communications developed by clinical professionals and designed to encourage them to improve their health behaviors by raising awareness of medication and lifestyle behaviors; the messages also included educational content and decision support. The presented noted that the ability to deliver these messages at relevant moments and based on real-time member data resulted in better clinical outcomes for the test group. Those outcomes included a 19% difference in reduction for all test group members, an 18% difference in reduction in test group members with Type 2 diabetes, and a 42% difference in reduction in a subset of test group members with Type 2 diabetes who were not using insulin treatment. “Digital therapeutics can play a key role in driving meaningful behavior change when the member experience is truly tailored to follow each person’s unique journey,” said DarioHealth chief medical officer Omar Manejwala, MD, in the press release. “This research is another example of how Dario is able to adapt and respond to our members using a combination of real-time data and clinically- guided, highly personalized interventions to drive healthier behaviors and deliver better results.”
To view the full press release, visit https://ibn.fm/5CUfC
About DarioHealth Corp.
DarioHealth is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. DarioHealth offers one of the most comprehensive digital therapeutics solutions on the market, covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health within one integrated technology platform. Dario’s next-generation, AI-powered, digital therapeutic platform supports more than just an individual’s disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions; intuitive, clinically proven digital tools; high-quality software; and coaching to help individuals improve health and sustain meaningful outcomes. Dario’s unique user-centric approach to product design and engagement creates an unparalleled experience that is highly rated by users and delivers sustainable results. The company’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology, utilizing a performance-based approach to improve users’ health. On the path to better health, Dario makes the right thing to do the easy thing to do. For more information about the company, please visit www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
